Pooled statistical meta-analyses and systematic reviews aggregating thousands of patients across multiple randomized controlled trials to measure true effect size. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
The current data encourages the use of semaglutide for managing WG or IWL post-bariatric surgery.
We found dutasteride 0.5 mg/day to be the most effective option.
64.6% for Bupropion), the combination's safety profile remained comparable, with no significant increase in treatment discontinuation.
This meta-analysis highlights the critical role of sleep disorders in dementia risk, emphasizing the need for early detection and management of sleep disturbances.
Further long-term studies are needed to draw definitive conclusions regarding the real-world benefits and safety of combination therapy with antidepressants and Z-drugs.
The effectiveness of Atorvastatin on the rise of HDL was 1.85 mg/dl (-3.23-0.46 and CI =95 %) versus Rosuvastatin with a rise of 3.87 mg/dl (2.08-5.66 and CI =95 %); and the effectiveness of atorvastatin on the reduction of TG...
While it may help with severe itching, it should not replace standard treatments.
Pioglitazone add-on therapy significantly improved glycaemic control by reducing HbA1c, fasting blood glucose and HOMA-IR while increasing the likelihood of achieving HbA1c targets.
Current literature supports tirzepatide demonstrating a higher impact on weight loss than semaglutide, with both demonstrating high rates of minimal- to moderate-severity AEs.
This meta-analysis establishes Semaglutide as the most effective GLP-1 receptor agonist for blood sugar control and weight reduction, while Dulaglutide and Exenatide offer viable alternatives with fewer side effects.
Elinzanetant reduces the frequency and intensity of VMS and enhances quality of life and sleep quality in patients with menopause-related symptoms.
There was no significant difference amongst most single agents when evaluating lesion count reduction.
Soft tissue surgery for OSA treatment in adults significantly resulted in long-term blood pressure reduction.
These findings position angiostatin as a dual-action therapeutic candidate, offering novel opportunities to simultaneously target vascular remodeling and immune dysregulation in AD.
There was no statistically significant difference between groups for the incidence of hypotension (RR 2.42; 95% CI 0.26-22.46; P = 0.44; I 2 = 0%).
LDOM appears to be a safe treatment for hair loss with no significant impact on blood pressure.
Females lost more weight than males when treated with GLP-1RAs for weight reduction.
CMNT significantly enhances hair count and diameter in AGA patients with mild side effects.
This analysis suggests that dietary flavonoids could potentially alleviate symptoms associated with PCOS.
The probabilities of agomelatine having the highest full symptom relief rate and lowest discontinuation (due to AEs) rate were 67% and 68%, respectively.
Findings related to obstructive sleep apnea syndrome were mixed.
Subcutaneous semaglutide can significantly decrease systolic and diastolic blood pressure, particularly in selected groups of patients.
These findings quantified the variability of telmisartan PK profile and highlighted the differences between healthy individuals and hypertensive patients, suggesting the need for optimized dosage strategies to improve...
GLP-1 agonists were effective in HbA1c and total daily insulin reduction among patients with T1DM.
Eight articles have been included to determine the correlation between obstructive sleep apnea syndrome and kidney injury, and it has been found that obstructive sleep apnea syndrome is closely related to kidney injury, and...
The rTMS could be an effective and safe treatment for patients with GAD.
BZDs are overall efficacious for the treatment of GAD and have a favorable safety profile.
Compared to placebo, both Semaglutide and tirzepatide are associated with increased GI adverse outcomes, with most cases being mild.
Pitavastatin poses a lower risk of NODM than other statins, making it a potentially safer option for patients requiring long-term statin therapy.
Milrinone, Sildenafil, and Sildenafil_Milrinone reduced the mortality of neonates with PPHN.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
